ProKidney shares soared over 500% after positive Phase 2 results for rilparencel in advanced CKD, showing significant improvement in kidney function decline. The company targets severe CKD patients, ...
ProKidney Corp. announced positive topline results from its Phase 2 REGEN-007 trial of rilparencel in patients with chronic kidney disease (CKD) and diabetes, indicating significant improvement in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback